2-Oct-12 7:00 AM  CST

FDA Approves Stivarga For Advanced Colorectal Cancer

The Food and Drug Administration (FDA) has approved Stivarga (regorafenib) to treat patients who suffer from colorectal cancer, which has progressed after cancer treatments and spread to various parts of a patient’s body.  Stivarga works by blocking various enzymes that promote cancer growth.  The new drug is marketed by Bayer HealthCare Pharmaceuticals.  

Pharmacy technicians should note that Stivarga has been officially approved, but with a black boxed warning.  In clinical trials severe and fatal liver toxicity was a result of taking Stivarga.  Common side-effects reported were weakness, fatigue, loss of appetite, hand-foot syndrome, diarrhea, mouth sores, weight-loss, infection, changes in voice volume/quality, and high blood pressure.       

“Stivarga is the latest colorectal cancer treatment to demonstrate an ability to extend patients lives and is the second drug approved for patients with colorectal cancer in the past two months,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in FDA’s Cancer for Drug Evaluation and Research. 

Pharmacy technicians will appreciate this very important new drug approval information, as it will help them stay abreast of new drugs they may see in the retail or hospital setting. 

Yao, Stephanie.  “FDA Approves New Treatment For Advanced Colorectal Cancer.”  FDA.gov.  Web.  27 Sept 2012.  

For additional information on this article, please contact:
Jennifer O'Reilly
Source: NPTAnews  

Tendenci™ User Home © 2004 Tendenci™ software by Schipul - "The Web Marketing Company" | www.schipul.com